Granules India Q2 FY27 Earnings Call: Record Revenue Crosses Rs. 15,600 Million, Plans Rs. 2,000 Crore Capex

Granules India Ltd held its Q2 FY27 earnings call on November 02, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Record Revenue Quarter, But Margin Pressure Builds

• Revenue of Rs.15,600 million, +20% YoY and +6% QoQ — the first quarter above Rs.15,000 million in company history and the eighth consecutive quarter of sequential revenue growth.
• EBITDA of Rs.3,376 million, +21% YoY — margin at 21.6%, up 19 bps YoY but down 131 bps QoQ on higher input and logistics costs from the West Asia conflicts.
• PAT rose 39% YoY to Rs.1,818 million — PBT of Rs.2,434 million (+38% YoY), with PBT margin improving ~200 bps to 15.6% from 13.6% in Q2 FY 2025-2026.
• Gross margin at 64.4%, down 134 bps YoY and 126 bps QoQ — driven by higher input costs from the West Asia conflicts, partly offset by lower-cost safety inventory carried into the USA.
• R&D spend of Rs.8,885 million (5.7% of sales), +26% YoY — intentionally focused on high-barrier areas: C2, ADHD, oncology, MUPs and complex formulations.
• Net cash of Rs.8,280 million at end of Q2 FY 2026-2027 — vs net debt of Rs.1,112 million in Q1 FY 2026-2027, driven by receipt of balance warrant proceeds.
• Operating cash flow fell to Rs.650 million from Rs.3,874 million in Q1 FY 2026-2027 — on a deliberate working capital increase (NWC-to-sales 30% vs 29%) and a planned US inventory build for supply continuity.

Form 483 Post-Warning-Letter: Addressable, But Timeline Uncommitted

• USFDA conducted a CGMP inspection of Gagillapur during October 19-30, 2026 — the first since the February 2025 warning letter (following the 2024 inspection), concluding with a Form 483; management assesses none of the observations relate to data integrity, cross-contamination, or facility upkeep.
• Response due within 15 business days — a comprehensive CAPA response will be submitted to the USFDA; CMD Krishna Prasad Chigurupati indicated resolution typically takes about 90-100 days from the date of response, though he hedged that "it all depends... how things go."
• 9 applications pending from the site — of which 2 have already been transferred to the company's US facility and will continue to be made there, no longer requiring Gagillapur approvals.
• Approvals process norm of 30-90 days after EIR receipt — per Priyanka Chigurupati, stated as a general FDA process norm (with VAI or MAI classification), not a company-specific date; she did not commit to a classification outcome or resolution timeline.
• Remediation plan complete except for two CAPAs — Priyanka Chigurupati confirmed the observations received were fresh, not part of the original warning letter; another on-site inspection is not believed to be required at this point, but the decision rests with the FDA.
• Remediation expenses to moderate significantly from Q4 FY 2026-2027 — Q3 FY 2026-2027 remediation spend expected to be similar to Q2 FY 2026-2027 (CFO Mukesh Surana).
• Analyst Sajal Kapoor flagged that the unresolved warning letter restricts new product onboarding, including patent manufacturing assignments — management did not directly address this concern.

Back-Ended FTF Pipeline; Five H2 FY27 Launches

• 5 launches planned in H2 FY 2026-2027 (Q3-Q4), all for the US market — 2 are controlled substances with very limited competition and large markets; none include the litigation-based products (generic Lumrys, sodium oxybate, ruxolitinib), for which management declined to guide on timing.
• Three potential sole first-to-file ANDAs filed — generic Dynavl XR (amphetamine-based extended-release ODT), sodium oxybate, and ruxolitinib; several more under development with filings targeted over the next 6 to 7 quarters, with timing and contribution dependent on regulatory and litigation outcomes and potentially uneven across quarters.
• First FTF launch guided at roughly 2.5-3 years away (≈FY 2029-2030) — explicitly subject to litigation; a second product that has been open for a while is to be filed shortly.
• 26 ANDAs awaiting approval — providing the pipeline for the next wave of launches; 8 products pending approval from GGP and 2-3 filed from GPI slated for Q3-Q4 FY 2026-2027 depending on approval timing.
• 8 filings completed in H1 FY 2026-2027 for global expansion — some subject to approvals within 6-12 months depending on target-country regulations; management expects these to yield short-to-medium-term revenues and contribute a large percentage of overall sales going forward.
• Zero launches completed in H1 FY 2026-2027 — analysts flagged FY 2027-2028 and FY 2028-2029 as potential "gap years" given the back-ended FTF pipeline; management pointed to launches pending US approvals, global expansion filings, and licensing of a few products as drivers, giving no specific revenue guidance for those years.
• Granules is No. 3 in the US in controlled substances (CNS) — market share varies product-to-product; the ADHD portfolio is primarily extended-release (complex category), with launch decisions tied to quota allocation and a strategy to maximize earnings per kg of quota.

Record Inquiry Momentum, But FY27 Targets Hinge on Q4 Execution

• H1 FY 2026-2027 peptide CDMO revenue of Rs.109 crores with ~Rs.28 crores cumulative EBITDA loss — figures cited by analyst Sajal Kapoor and not disputed by management; hitting the FY 2026-2027 minimum revenue target of Rs.240 crores requires H2 revenue of ~Rs.131 crores, ~21% larger than H1.
• FY27 expected to close between EBITDA neutrality and PAT neutrality — depending on product/project mix; management expressed hope of achieving its stated ambition of PAT profitability by end of FY27, with the key being smooth Q4 FY 2026-2027 execution when customer offtakes peak.
• Highest inquiry period in the last four months — CEO Sanjay Kumar attributed this to BD outreach measures; translation into material revenue movement depends on execution over the next few quarters (Q3 FY 2026-2027 onward), and he gave no specific timeline for commercial-scale revenues, noting RFP/RFQ-to-commercial translation "takes a while."
• $10 million+ win criterion from Q1 FY 2026-2027 (3 wins targeted) remains under discussion — not yet signed; Sanjay Kumar disputed the analyst's reference to $200 million+ annually, stating that number was never projected.
• Sentide's Sen Chemical site in Zurich completed its Swissmedic GMP inspection in Q2 FY 2026-2027 with no critical findings — meaningful progress versus the previous inspection two years ago; a theragnostic-related project was revived after nearly two years, and supply partnerships were renewed with two major peptide CDMO players.
• Rs.300 crore India capex at Vizag will proceed regardless of customer tie-ups — explicitly not contingent; the project team is in place planning the proposed integrated peptide manufacturing facility, with oligonucleotide scientific leadership on board and additional team members joining over Q3 FY 2026-2027.

Gross Margin Gains Not Flowing Through; Utilization Is the Lever

• Gross margin expanded ~1,900 bps from 46-47% (March 2016) to 65%+ currently, yet EBITDA margin stayed broadly flat at 20-21% then vs 21-22% now — CFO Mukesh Surana attributed this to a changed cost base: higher R&D, the shift from API to formulations and complex generics, and significantly higher employee costs in the US and at Sentide.
• Even at 100% cost pass-through, margin percentage would arithmetically decline — Surana said cost pressures are continuing, customer price pass-on follows with a lag, and margins in subsequent quarters of FY 2026-2027 may "vary a little bit here and there," with the focus on growing profit in line with internal plans.
• Genome Valley (GLS) at 25% utilization, expected to cross 50% by Q4 FY 2026-2027 — Surana said GLS will generate additional double-digit ROCE once it reaches optimal utilization (period unspecified).
• Gagillapur at ~75% utilization, unchanged despite the inspection — additional revenue potential from product mix optimization and further utilization gains; demand for the site increased in H1 FY 2026-2027, with H1 awards to be serviced from December 2026/January 2027.
• Consolidated ROCE of 17.6% vs core business ROCE of ~25% flagged by analyst Yash Mehta — Surana said the investment hurdle rate is not to drag down ROCE and that ROCE will keep inching up as investments mature, giving no specific timeline for narrowing the gap; the peptide CDMO business remains loss-making.
• Management declined to quantify medium-term or 3-year EBITDA margin improvement — citing dynamic crude prices and ongoing customer discussions on price pass-on; targets absolute profit growth in FY 2026-2027.

Rs.2,000 Crore Capex Plan; No Formal Guidance Reiterated

• Rs.2,000 crore organic growth capex planned over the next 3-4 years (through ~FY 2030-2031) — allocated to peptide CDMO infrastructure (Zurich and India), US platform manufacturing and distribution, oncology launch-related capacity, and multiple API expansions based on utilization levels (CFO Mukesh Surana).
• Capex mix not necessarily brownfield — includes formulations capacity for complex and oncology products, downstream API, warehouse and distribution improvement, and significant IT digitalization investment for quality management and manufacturing capabilities; Surana expects the capex to deliver strong double-digit ROCE (period unspecified).
• Q2 FY 2026-2027 capex of Rs.1,304 million — vs Rs.890 million in Q1 FY 2026-2027 and Rs.2,112 million in Q2 FY 2025-2026, to strengthen manufacturing and packaging capabilities; ROC at 17.6%, up 138 bps YoY.
• No formal guidance reiterated for FY27 — CFO Mukesh Surana stated the current rate of growth and progress will continue with no change, but gave no specific revenue growth or EBITDA margin figures for FY 2026-2027; API/PFI growth is expected to follow a similar trajectory in H2 FY 2026-2027, predominantly captive and volume-driven, with LATAM expansion being pursued.
• Medium-term portfolio guidance of 50% complex generics in formulations reiterated — complex generics grew 38% YoY in Q2 FY 2026-2027 but its share declined to 47% from 50% in Q1 FY 2026-2027 (integrated generics rose to 48% from 46%); Surana said the company is ahead of what it has stated and will probably exceed 50% in the medium term (specific FY not provided).
• US to remain the biggest market "for the foreseeable future" — strategy rests on controlled substances under the Make in America platform, complex generics/early market entry, geographical expansion, oncology, and peptide CDMO; management expects industry-wide geopolitical pressure on input and logistics costs to persist, with customer price adjustments following with a lag.